File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study

TitleThe mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study
Authors
Keywordsleiomyosarcoma
smooth muscle tumour of uncertain malignant potential
uterus
leiomyoma with bizarre nuclei
phosphohistone-H3
Issue Date2017
Citation
Histopathology, 2017, v. 70, n. 5, p. 746-755 How to Cite?
Abstract© 2016 John Wiley & Sons Ltd Aims: Accurate mitosis counting, which is important in the diagnosis of uterine smooth muscle tumours (USMTs), is often difficult and subjective. The mitosis-specific immunohistochemical marker phosphohistone-H3 (PHH3) has been shown to be diagnostically useful, but its expression, in relation to outcome, has not been thoroughly investigated. The aim of this study is to evaluate PHH3 as a diagnostic and prognostic marker in USMTs. Methods and results: PHH3 expression was evaluated in 55 leiomyosarcomas (LMSs), 26 smooth muscle tumours of uncertain malignant potential (STUMPs), 18 leiomyomas with bizarre nuclei (LBN), and 12 leiomyomas (LMs). Scores were expressed as counts per 10 high-power fields (HPFs). Median follow-up durations of patients with LMS, STUMP, LBN and LM were, respectively, 39, 78, 65.5 and 49.5 months. Twenty-eight patients with LMSs (50.9%) died, and two (7.7%) patients with STUMPs experienced recurrence. The median PHH3 scores for LMSs were significantly higher than those for other categories of tumour. A score of ≥29/10 HPFs was also independently associated with a poor outcome. To test whether the PHH3 score could distinguish between benign USMTs with atypical histology and those that were clinically malignant, two biological groups were further delineated. Patients in group 1 (18 LBNs and 24 STUMPs) all had an uneventful outcome, whereas patients in group 2 (two recurrent STUMPs and 32 LMSs) all had a recurrence or tumour-related death. Median PHH3 scores for the two groups were, respectively, 2/10 HPFs and 27/10 HPFs. A PHH3 score of ≥7/10 HPFs was highly associated with malignancy. Conclusion: PHH3 is useful in evaluation of the biological behaviour of USMTs, and may serve as a prognostic indicator for LMSs.
Persistent Identifierhttp://hdl.handle.net/10722/254578
ISSN
2015 Impact Factor: 3.425
2015 SCImago Journal Rankings: 1.488

 

DC FieldValueLanguage
dc.contributor.authorChow, Kin Long-
dc.contributor.authorTse, Ka Yu-
dc.contributor.authorCheung, Ching Lung-
dc.contributor.authorWong, Ka Wing-
dc.contributor.authorCheung, Annie N.Y.-
dc.contributor.authorWong, Richard W.C.-
dc.contributor.authorChan, Alice N.H.-
dc.contributor.authorYuen, Nancy W.F.-
dc.contributor.authorNgan, Hextan Y.S.-
dc.contributor.authorIp, Philip P.C.-
dc.date.accessioned2018-06-19T15:40:56Z-
dc.date.available2018-06-19T15:40:56Z-
dc.date.issued2017-
dc.identifier.citationHistopathology, 2017, v. 70, n. 5, p. 746-755-
dc.identifier.issn0309-0167-
dc.identifier.urihttp://hdl.handle.net/10722/254578-
dc.description.abstract© 2016 John Wiley & Sons Ltd Aims: Accurate mitosis counting, which is important in the diagnosis of uterine smooth muscle tumours (USMTs), is often difficult and subjective. The mitosis-specific immunohistochemical marker phosphohistone-H3 (PHH3) has been shown to be diagnostically useful, but its expression, in relation to outcome, has not been thoroughly investigated. The aim of this study is to evaluate PHH3 as a diagnostic and prognostic marker in USMTs. Methods and results: PHH3 expression was evaluated in 55 leiomyosarcomas (LMSs), 26 smooth muscle tumours of uncertain malignant potential (STUMPs), 18 leiomyomas with bizarre nuclei (LBN), and 12 leiomyomas (LMs). Scores were expressed as counts per 10 high-power fields (HPFs). Median follow-up durations of patients with LMS, STUMP, LBN and LM were, respectively, 39, 78, 65.5 and 49.5 months. Twenty-eight patients with LMSs (50.9%) died, and two (7.7%) patients with STUMPs experienced recurrence. The median PHH3 scores for LMSs were significantly higher than those for other categories of tumour. A score of ≥29/10 HPFs was also independently associated with a poor outcome. To test whether the PHH3 score could distinguish between benign USMTs with atypical histology and those that were clinically malignant, two biological groups were further delineated. Patients in group 1 (18 LBNs and 24 STUMPs) all had an uneventful outcome, whereas patients in group 2 (two recurrent STUMPs and 32 LMSs) all had a recurrence or tumour-related death. Median PHH3 scores for the two groups were, respectively, 2/10 HPFs and 27/10 HPFs. A PHH3 score of ≥7/10 HPFs was highly associated with malignancy. Conclusion: PHH3 is useful in evaluation of the biological behaviour of USMTs, and may serve as a prognostic indicator for LMSs.-
dc.languageeng-
dc.relation.ispartofHistopathology-
dc.subjectleiomyosarcoma-
dc.subjectsmooth muscle tumour of uncertain malignant potential-
dc.subjectuterus-
dc.subjectleiomyoma with bizarre nuclei-
dc.subjectphosphohistone-H3-
dc.titleThe mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1111/his.13124-
dc.identifier.pmid27864989-
dc.identifier.scopuseid_2-s2.0-85010808959-
dc.identifier.hkuros273945-
dc.identifier.volume70-
dc.identifier.issue5-
dc.identifier.spage746-
dc.identifier.epage755-
dc.identifier.eissn1365-2559-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats